In his weekly clinical update, Dr. Griffin discusses the detection of circulating vaccine-derived poliovirus type 2 in Burundi and the Democratic Republic of the Congo, the novel oral polio vaccine type 2 story, prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction, adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection, correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel, effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths in people with COVID-19, projected COVID-19 mortality reduction from Paxlovid rollout, and SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
Click arrow to play Download TWiV 994 (26 MB .mp3, 43 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- cVDPV2 detections in Burundi and the DRC (PGEI) 4:52
- Novel oral polio vaccine type 2 story (The Lancet) 6:59
- Prior COVID-19 infection associated with risk of diagnosed erectile dysfunction (IJIR) 8:17
- Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection (BMJ) 13:37
- Protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals (The Lancet) 15:00
- Effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths (The Lancet) 25:30
- Projected COVID-19 mortality reduction from Paxlovid rollout (JAMA)
- SARS-CoV-2 mRNA vaccines decouple anti-viral immunity (Nature) 30:50
- Contribute to our ASTMH fundraiser at PWB
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 994 36:15
- Don’t crush Paxlovid (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Leave a Reply